TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05572749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crocus Kozanis
Description: In this study, intervention will be the administration of Crocus Kozanis dietary supplement. Crocus Kozanis is a herb which is cultivated in Kozani, Greece.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crocus Kozanis
Description: In this study, intervention will be the administration of Crocus Kozanis dietary supplement. Crocus Kozanis is a herb which is cultivated in Kozani, Greece.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Crocus Kozanis
Description: Placebo of Crocus Kozanis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered in a dosage of 1000mg per day. Metformin is a formally approved therapy for children with diabetes in Europe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered in a dosage of 1000mg per day. Metformin is a formally approved therapy for children with diabetes in Europe.
Study: NCT05184270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic stimulation
Description: In this project, the intervention is a presentation of low-volume non-arousing auditory stimuli during deep NREM sleep via attached headphones. Stimuli will be applied targeting the up-phase of slow waves to enhance sleep slow-wave activity.~Previous studies showed that this procedure does not lead to reduced sleep quality nor result in changed sleep architecture. Therefore, no negative consequences as a result of our intervention are to be expected. In fact, it is currently applied in several other studies including children, adults, and the elderly. Importantly, stimulation is not arousing, as the sounds presented during deep sleep are brief (50 ms) and at low volume (around 50 dB). In case of arousal during sleep (detected using the surface EEG signal), the volume will be adjusted.
Study: NCT05323630

Intervention type: DEVICE
Group type: OTHER
Intervention: Renuvion APR System
Description: The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
Study: NCT04584892

Intervention type: DRUG
Intervention: Turoctocog alfa
Description: Patients will be treated with commercially available NovoEight® (turoctocog alfa) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available NovoEight® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study: NCT05241444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4^LVFOXP3
Description: Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of:~i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4\^LVFOXP3 in the blood.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4^LVFOXP3
Description: Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of:~i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4\^LVFOXP3 in the blood.
Study: NCT05957185

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OPTIZIOME® P³ HYDROLYZER® - WHEY
Description: One dose of P3 - WHEY will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo maltodextrain will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
Study: NCT05417347

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat dairy products
Description: Milk: low fat (less than 2% M.F.) Yogurt: less than 2% M.F. Cheese: less than 20% M.F.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full-fat dairy products
Description: Milk: full-fat milk Yogurt: 2% and more M.F. Cheese: Regular cheese products
Study: NCT06172790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: A protocol has been established for the progression of the strengthening and balance training components of the Otago Exercise Program, increasing every two weeks in a four-stage manner. The exercise intensity will be gradually increased based on patient tolerance, ensuring that the perceived difficulty level remains in the range of 4-6 on the Borg dyspnea scale throughout the 8-week period. Supervised walking training is planned to be conducted on a treadmill to ensure standardization. The initial treadmill walking speed for patients will be determined based on the submaximal walking speed in the 6-minute walking test. The progression of the walking program will be carried out every two weeks, similar to the other exercise components of the program, with a 10% increase in walking speed each time.
Study: NCT05981014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy (SLNB)
Description: A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study: NCT06142435

Intervention type: DEVICE
Intervention: Head and Intraocular Trauma Tool
Description: HITT device to scan the eyes of participants up to 3 times (\~45 seconds each) at the time of admittance to study. The participant is to place the chin in the chin-rest and fixate on the illuminated light on the device.

Intervention type: DEVICE
Intervention: Head and Intraocular Trauma Tool
Description: HITT device to scan the eyes of participants up to 3 times (\~45 seconds each) at the time of admittance to study. The participant is to place the chin in the chin-rest and fixate on the illuminated light on the device.
Study: NCT06144944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
Description: Pyrotinib 320 mg orally once daily, and epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
Description: Epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
Study: NCT05640167

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interdisciplinary Clinic
Description: Interdisciplinary Clinic - assessment and recommendations by Nutrition, Pharmacy, Physical Therapy, and Speech Therapy and Educational Seminar - Parkinson's specific education and resources in group format
Study: NCT04287192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Bridge:Tool Intervention
Description: Our Digital Bridge is an integration of the Care Connector and ePRO technologies that will support care transitions by: 1) inviting PCPs to access Care Connector while the patient is in hospital, allowing for asynchronous communication via the messaging feature for proactive discharge planning, 2) facilitating the inclusion of inter-professional recommendations in the discharge module (e.g. diet and mobility) typically missing from traditional physician generated discharge summaries, 3) electronic generation of PODS for use in patient-centred discharge teaching, 4) providing patients electronic access to PODS post discharge to facilitate use of information at home, 5) adoption of digital enabled goal-oriented process to engage patients and families in discharge process, and 6) providing ongoing self-management support for patients using ePRO for the vulnerable period 6 months post discharge.
Study: NCT04103554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: standard of care used for treating BP
Study: NCT05716737

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation
Description: 3 Gy in 6 fractions to the TMJ, every other day, LINAC based
Study: NCT06078592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRIDIN-plus Eye drops
Description: One drop in the eyes, twice a day, approximately 12 hours apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combigan Eye drops
Description: One drop in the eyes, twice a day, approximately 12 hours apart.
Study: NCT05981014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-draining lymph node-derived lymphocyte (LNL)
Description: In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
Study: NCT06046131

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Extra blood collection for dosages Urine collection for the dosage of non-persistent pollutants, isolation of extracellular vesicles released in urine, analysis of the microbiome, metagenomics to obtain a complete description of the bacterial functions represented as well as other microorganisms present, metabolome profiling and identification and/or assays of any other biological compound of interest strictly related to the specific objectives of the research.~Saliva collection for the extraction of the constitutional DNA. An interview using a structured questionnaire A quality of live auto-questionnaire
Study: NCT04183010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity coaching
Description: Interventions will be delivered via smartphone and will consist of physical activity coaching. Once randomized to the Coaching arm, individuals will be presented with seven broad categories of physical activity. They will receive a daily notification on their phone indicating that they have study activities to complete. They will then click on this notification and will be offered five options:~1. A low intensity activity from one of the categories they selected upon start of coaching~2. A moderate-to-vigorous endurance activity~3. The participant will be linked to video content with exercise tutorials/video coaching~4. Option to skip exercise that day~5. Option to fill in a different activity that the participant completed (free text entry)~The participant will then select one of these options and complete the chosen activity. They will be presented with the question Did you completed the exercise with three options:~1. Yes~2. No~3. Give me a different exercise
Study: NCT05061199

Intervention type: PROCEDURE
Intervention: approach of anastomosis
Description: The approach of anastomosis

Intervention type: PROCEDURE
Intervention: approach of anastomosis
Description: The approach of anastomosis
Study: NCT05141396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth- enabled support for SAT/SBT adherence
Description: Telehealth-enabled support over and above usual audit and feedback includes identifying candidates for spontaneous awakening and breathing trials, prompting bedside providers and guiding execution of the coordinated spontaneous awakening and breathing trials as needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual audit and feedback for SAT/SBT adherence
Description: Usual audit and feedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual audit and feedback for SAT/SBT adherence
Description: Usual audit and feedback
Study: NCT06074692

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
Description: Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
Description: Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
Description: Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)
Study: NCT05272709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-702
Description: TT-702 will be administered orally, once daily, for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-702
Description: TT-702 will be administered orally, once daily, for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-702
Description: TT-702 will be administered orally, once daily, for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-702
Description: TT-702 will be administered orally, once daily, for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-702
Description: TT-702 will be administered orally, once daily, for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-702
Description: TT-702 will be administered orally, once daily, for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide will be administered orally, twice daily, for up to 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide will be administered orally, twice daily, for up to 12 months.
Study: NCT05282251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrapleural bupivacine nebulization
Description: Intrapleural nebulization of bupivacine (10 ml of bupivacaine 0.5%) + Intravenous normal saline as a placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol and ketorolac
Description: Intravenous analgesia: paracetamol (one gram) and Ketorolac (30 mg) + Intrapleural normal saline (10 ml) as a placebo
Study: NCT05194163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW150
Description: oral-delivered capsule of study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral delivered capsule matched to study drug capsule
Study: NCT05823974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu mRNA
Description: Different formulations of Flu mRNA (GSK4382276A) study intervention is administered intramuscularly in the non-dominant upper deltoid to YA and OA participants in Phase 1 and Phase 2, at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu mRNA
Description: Different formulations of Flu mRNA (GSK4382276A) study intervention is administered intramuscularly in the non-dominant upper deltoid to YA and OA participants in Phase 1 and Phase 2, at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu mRNA
Description: Different formulations of Flu mRNA (GSK4382276A) study intervention is administered intramuscularly in the non-dominant upper deltoid to YA and OA participants in Phase 1 and Phase 2, at Day 1.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control 1
Description: Control 1 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control group from Phase 1, at Day 1 and to participants in Control YA group from Phase 2, at Day 1.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control 1
Description: Control 1 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control group from Phase 1, at Day 1 and to participants in Control YA group from Phase 2, at Day 1.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control 2
Description: Control 2 vaccine is administered intramuscularly in the non-dominant upper deltoid to participants in Control OA group from Phase 2, at Day 1.
Study: NCT06545318

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Density Gradient Centrifugation
Description: Sperm separation with density gradients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CA0 chamber
Description: Sperm separation with a novel device
Study: NCT04692805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coils
Description: EUS-guided injection of coils

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coils
Description: EUS-guided injection of coils

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyanoacrylate glue
Description: EUS-guided injection of cyanoacrylate glue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyanoacrylate glue
Description: EUS-guided injection of cyanoacrylate glue
Study: NCT06487143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate（15mg）
Description: Triptorelin pamoate 15mg is administered via intramuscular injection once every three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate （3.75mg）
Description: Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.
Study: NCT05421156

Intervention type: PROCEDURE
Intervention: Subtotal Laparoscopic Hysterectomy
Description: Subtotal laparoscopic hysterectomy involves removing the main body of the uterus and leaving the cervix in place by laparoscopy.

Intervention type: PROCEDURE
Intervention: Total Laparoscopic Hysterectomy
Description: Total laparoscopic hysterectomy involves removing the whole uterus and cervix by laparoscopy
Study: NCT05471440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct boost mRNA
Description: Participants will be boosted with a covid-19 vaccin after priming with mRNA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct boost adeno
Description: Participants will be boosted with a covid-19 vaccin after priming with adeno

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-poned boost mRNA
Description: Participants will be boosted with a covid-19 vaccin after priming with mRNA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-poned boost adeno
Description: Participants will be boosted with a covid-19 vaccin after priming with adeno